ESSA Pharma Inc. Files 8-K: Material Agreement and Other Events

Essa Pharma Inc. 8-K Filing Summary
FieldDetail
CompanyEssa Pharma Inc.
Form Type8-K
Filed DateJul 14, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, filing, corporate-event

TL;DR

ESSA Pharma filed an 8-K for a material agreement and other events on July 13, 2025.

AI Summary

On July 13, 2025, ESSA Pharma Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements and exhibits as part of this 8-K filing. Specific details of the agreement and financial information were not provided in the excerpt.

Why It Matters

This filing indicates a significant development for ESSA Pharma Inc., potentially involving new partnerships, acquisitions, or financial arrangements that could impact its future operations and stock value.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks for the company, but the lack of specific details makes a precise risk assessment difficult.

Key Players & Entities

  • ESSA Pharma Inc. (company) — Registrant
  • July 13, 2025 (date) — Date of earliest event reported
  • 001-37410 (company) — Commission File Number
  • 98-1250703 (company) — IRS Employer Identification No.
  • Vancouver, British Columbia, Canada (location) — Principal executive offices
  • (778) 331-0962 (phone_number) — Registrant's telephone number

FAQ

What is the nature of the material definitive agreement entered into by ESSA Pharma Inc. on July 13, 2025?

The provided excerpt does not specify the details of the material definitive agreement.

What are the 'Other Events' reported by ESSA Pharma Inc. in this 8-K filing?

The excerpt mentions 'Other Events' as an item information but does not provide specific details about them.

What financial statements and exhibits are included with this 8-K filing?

The filing indicates that financial statements and exhibits are included, but the excerpt does not list them.

Where are ESSA Pharma Inc.'s principal executive offices located?

ESSA Pharma Inc.'s principal executive offices are located at Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5.

What is the Commission File Number for ESSA Pharma Inc.?

The Commission File Number for ESSA Pharma Inc. is 001-37410.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 14, 2025 regarding ESSA Pharma Inc..

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.